Időskori makuladegeneráció: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• VEGF 19
• NRF2 0
• GLP-1 0
• PPAR 0
• AKT 0
• JNK 0
• APOE 0
• PI3K 0
• SIRT1 0
• ALK 1
• AMPK 0
• MAPK 0
• mTOR 0
• GPX4 0
• JAK 0
• NLRP3 0
• TP53 0
• ERK 0
• PCSK9 0
• STAT3 0
• STING 0
• YAP 0
• BCL-2 0
• CTNNB1 0
• CXCR4 0
• HIF-1 0
• IL-6 0
• MMP-9 1
• PDGFR 0
• SGLT2 1
• TNF 0
• IL-17 0
• MDM2 0
• MYC 0
• NOTCH3 0
• PKM2 0
• RPGR 0
• SOD1 0
• TERT 0
• TFEB 0
• TREM2 0

1+ intézményből 1, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NEI · R43

  PRMT5 Inhibitors as a Novel Therapy for Anti-VEGF-Sensitive and -Resistant Neovascular Age-Related Macular Degeneration

  Eqon Pharmaceuticals, Llc· Carmel, Egyesült Államok· 233 247 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NEI · R01

  Metabolic tuning and signaling in retinal health and disease

  University of Wisconsin-Madison· Madison, Egyesült Államok· 608 985 USD awarded in fiscal year 2026· until 2030. aug.

• NIH NEI · R21

  Leveraging Ocular B cells to identiry antigen triggers in uveitis

  University of Colorado Denver· Aurora, Egyesült Államok· 429 000 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NEI · U01

  RURAL Eye Health Study

  Southern California Eye Institute· Los Angeles, Egyesült Államok· 1 089 223 USD awarded in fiscal year 2026· until 2031. máj.

• NIH NEI · R01

  Identifying barriers to retinal Muller glial reprogramming

  University of California, San Diego· La Jolla, Egyesült Államok· 499 606 USD awarded in fiscal year 2026· until 2030. jún.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Decoding retinal cell communication to counteract vision loss in aging (VisionGuard)

  Aarhus Universitet· Aarhus C, Dánia· EU contribution 263 393 EUR· until 2029. ápr.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Drusen Reconstitution in an Engineered AMD Model using Retinal Pigment Epithelium (DREAM_RPE)

  Universidade Nova de Lisboa· Lisboa, Portugália· EU contribution 207 183 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Doctoral network on discovering pathomechanisms and novel drug optimization for AMD (PANDORA)

  Eberhard Karls Universitaet Tuebingen· Tuebingen, Németország· EU contribution 4 020 973 EUR· until 2030. szept.· 8 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Full field optoretinography for elderly eye health (FFORGE)

  Institut National de la Sante Et de la Recherche Medicale· Paris, Franciaország· EU contribution 150 000 EUR· until 2028. febr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Lysophagy as a new strategy for neuroprotection in dry AMD (AMD_Prog)

  Universite de Fribourg· Fribourg, Svájc· EU contribution 307 959 EUR· until 2028. aug.

10 of 349 running projects, newest first. Listed amounts together: 183,6 M USD + 21,9 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 5
• Organoids 11
• Mendelian Randomization Analysis 26
• CRISPR-Cas Systems 7
• Gene Expression Profiling 16
• Sequence Analysis, RNA 3
• Whole Genome Sequencing 1
• Exome Sequencing 2
• Proteomics 21
• Metabolomics 16
• Mass Spectrometry 11
• Flow Cytometry 8
• Immunohistochemistry 15
• Liquid Biopsy 1
• Magnetic Resonance Imaging 6
• Machine Learning 14
• Deep Learning 31
• Cohort Studies 26
• Genome-Wide Association Study 24

• Incidence of Acute Cystoid Macular Edema After Penetrating Keratoplasty and Endothelial Keratoplasty.

  Klin Monbl Augenheilkd, 2026. aug.

• Real-World Faricimab for Treatment-Naïve Neovascular AMD and Diabetic Macular Edema: 24-Month Outcomes from a Single-Center Pilot Cohort in South-Eastern Europe.

  Medicina (Kaunas), 2026. júl.

• ORBIT-AMD: Ordinal Risk, Bilateral Imaging, and Trajectory Learning for Age-Related Macular Degeneration in Multi-Cohorts.

  Adv Sci (Weinh), 2026. jún.

• Home OCT Monitoring as a Safety Net for Early Detection of Recurrent Disease Activity in Neovascular Age-Related Macular Degeneration Under Standard Care.

  Medicina (Kaunas), 2026. jún.

• Clinical Outcomes of Anti-VEGF Monotherapy Versus Combination Therapy in Diabetic Macular Edema: A Retrospective Cohort Study.

  J Vis Exp, 2026. ápr.

• Age-related macular degeneration and dementia: Association through pathogenesis or visual impairment?

  J Alzheimers Dis, 2026. ápr.

• Remote Management of Patients With Diabetic Macular Edema Receiving Long-Term Intravitreal Anti-Vascular Endothelial Growth Factor Therapy (RE-SHINE Study): Protocol for a Real-World Study.

  JMIR Res Protoc, 2026. ápr.

• Traffic noise, air pollution, and greenness in relation to age-related macular degeneration: Evidence from a cross-national cohort study.

  Environ Pollut, 2026. ápr.

• Physical activity and the risk of cataract and age-related macular degeneration: a systematic review and meta-analysis of cohort studies.

  BMC Ophthalmol, 2026. márc.

• Association Between Pseudoexfoliation Glaucoma and Central Serous Chorioretinopathy.

  Am J Ophthalmol, 2026. márc.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.